|
|
||||||||
Division of Clinical Pharmacology and Toxicology, Departments of 1 Internal Medicine and 4 Obstetrics, University Hospital and 3 Electron Microscopy Laboratory, University of Zürich, CH-8091 Zürich, Switzerland; and 2 Departments of Biochemistry and Physiology, School of Pharmacy, University of Salamanca, 37007 Salamanca, Spain
| |
ABSTRACT |
|---|
|
|
|---|
The placenta serves, in part, as a
barrier to exclude noxious substances from the fetus. In humans, a
single-layered syncytium of polarized trophoblast cells and the fetal
capillary endothelium separate the maternal and fetal circulations.
P-glycoprotein is present in the syncytiotrophoblast throughout
gestation, consistent with a protective role that limits exposure of
the fetus to hydrophobic and cationic xenobiotics. We have examined
whether members of the multidrug resistance protein (MRP) family are
expressed in term placenta. After screening a placenta cDNA library,
partial clones of MRP1, MRP2, and MRP3 were identified.
Immunofluorescence and immunoblotting studies demonstrated that MRP2
was localized to the apical syncytiotrophoblast membrane. MRP1 and MRP3
were predominantly expressed in blood vessel endothelia with some
evidence for expression in the apical syncytiotrophoblast.
ATP-dependent transport of the anionic substrates
dinitrophenyl-glutathione and estradiol-17-
-glucuronide was also
demonstrated in apical syncytiotrophoblast membranes. Given the
cellular distribution of these transporters, we hypothesize that MRP
isoforms serve to protect fetal blood from entry of organic anions and
to promote the excretion of glutathione/glucuronide metabolites in the
maternal circulation.
placenta transport; human multidrug resistance protein 1; human multidrug resistance protein 2; human multidrug resistance protein 3
| |
INTRODUCTION |
|---|
|
|
|---|
IN THE TERMINAL VILLI of human placenta at term, the barrier between the maternal and fetal blood consists of a single-layered syncytium of polarized epithelial cells, the syncytiotrophoblast, a sparse number of cytotrophoblasts, and the villus stroma, which are separated from the fetal endothelium by a basement membrane (44). The passage of solutes between the maternal and fetal blood in either direction requires translocation across the maternal-facing apical brush-border and fetal-facing basolateral membranes of the syncytiotrophoblast as well as across the endothelium of the fetal capillaries. The removal of end products of metabolism by the placenta is vital when the fetal renal and hepatic systems have insufficient excretory capacities (24). The fetal liver synthesizes and metabolizes organic compounds that undergo minimal biliary excretion, among which are bile salts, anionic amphipathic compounds derived from the catabolism of cholesterol (9). Fetal bile salts are vectorially translocated from the fetal to the maternal circulation for elimination (35). At the apical brush-border membrane of the syncytiotrophoblast, bile salt transport is partially ATP dependent (5, 35), suggesting that a member of the ATP-binding cassette (ABC) superfamily of membrane transporters pumps these compounds in the intervillous maternal blood. At this time, only two ATP-dependent ABC cassette transporters have been localized to the trophoblastic tissue of human placenta: the cystic fibrosis transmembrane conductance regulator (CFTR; see Refs. 14 and 40) and P-glycoprotein multidrug resistance gene product 1 (MDR1; see Refs. 10, 40, 48). CFTR presumably mediates chloride transport at the apical membrane of the syncytiotrophoblast (14). The P-glycoprotein present in apical syncytiotrophoblast may function as an ATP-driven efflux pump to limit exposure of the fetus to toxic cationic xenobiotics. ATP-dependent uptake of vincristine has been demonstrated in membrane vesicles of cytotrophoblasts (42). In P-glycoprotein-deficient mice, the placental MDR1 content correlated with fetal exposure and toxicity to an analog of avermectin, a known substrate of MDR1 (31). The expression of the multidrug resistance protein (MRP) family, which preferentially transports organic anions such as glucuronide and glutathione conjugates (22, 23), has not been studied. Immunohistochemistry studies have reported both the presence (15) and the absence (48) of MRP1 in the syncytiotrophoblast of term placenta. Furthermore, there have been no functional studies associated with their presence in human placenta. Because it is important to predict fetal exposure to a range of xenobiotics present in maternal blood, we investigated the expression of organic anion transporters in the human placenta at term.
| |
METHODS |
|---|
|
|
|---|
Materials.
Radiolabeled 1-chloro-2,4-dinitro-[14C]benzene (Amersham
Switzerland) was used to synthesize the radiolabeled glutathione
conjugate, dinitrophenyl-glutathione (DNP-SG), according to the method
of Ishikawa (21). Glutathione and glutathione
S-transferase were from Sigma Chemie. ATP, creatine kinase,
and creatine phosphate were from Boehringer. Nitrocellulose filters
(0.65 µm) were from Sartorious.
[6,7-3H]estradiol-17-
-D-glucuronide was
from New England Nuclear (Boston, MA). Tritiated glycocholate was a
gift from Dr. A. Hofmann (La Jolla, CA).
RT-PCR. Total RNA from human placenta was extracted as described by Chomczynski and Sacchi (7). mRNA was isolated with the Poly(A)tract mRNA Isolation System (Promega, Madison, WI). Placental mRNA and human liver mRNA as a positive control were primed with oligo(dT) and reverse transcribed (SuperScript II; Life Technologies). As a negative control, template mRNA was processed without RT. The resulting cDNA was amplified by PCR with several sets of specific primers for the human MRP1, MRP2, and MRP3 nucleotide sequences. For MRP1 (EMBL/GenBank accession number L05628), 25 cycles of PCR with primers 5'-GATCAACGAGTCTGCC-3' (forward) and 5'-CAGCTCTGGGGCTCAC-3' (reverse) followed by nested PCR with primers 5'-GGCATCAACATCGCCAAGA-3' (forward) and 5'-AAGACCTCTCTGCTGCAGG-3' (reverse) yielded a product of 495 bp. For human MRP2 (X96395), the specific primers were 5'-CTGCCTGTTCTTCATCTC-3' (forward) and 5'-TACCCCTGCCTGTTCTTC-3' (reverse), which gave a 1,800-bp PCR product. For human MRP3 (Y17151), the specific primers 5'-CTGCTGATTGAAGACACAC-3' (forward) and 5'-TACTCCTTGACCCTCTCCAC-3' (reverse) gave a PCR product of 1,150 bp. PCR products were ligated (SureClone Ligation Kit; Pharmacia Biotech) into the PUC19 vector and transformed into MaxDH500 competent bacteria (Life Technologies). Sequencing of plasmid inserts was performed on an ALFexpress DNA Sequencer (Pharmacia Biotech). The subcloned RT-PCR products were used as probes to screen a placenta cDNA library (Origene Technologies, Rockville, MD).
Cloning of human placental MRP homologs. The cDNA library panel was screened by PCR with DyNAzyme EXT DNA polymerase (Finnzymes) and the specific primers for MRP1, MRP2, and MRP3. Subplates containing Escherichia coli glycerol stocks were screened with the same primers in a second round. Positive colonies were identified by hybridization with probes radiolabeled with [32P]dCTP by the random-primed method. Inserts were sequenced as described.
Membrane preparations.
Membrane vesicles were prepared from healthy placentas before the onset
of labor and within 30 min of scheduled caesarian deliveries.
Basolateral (fetal-facing) trophoblastic vesicles were purified
according to a modified method of Kelley et al. (25, 35).
Apical trophoblastic vesicles (maternal-facing) were prepared according
to an adaptation (5) of the method of Booth et al.
(3). Basolateral vesicles were characterized as described
(13), by measuring binding of the
-adrenergic antagonist dihydroalprenolol to assess enrichment (49) and
ouabain binding in the presence and absence of detergent to assess the orientation and integrity of the vesicles (34). The
enrichment and orientation of apical vesicles were characterized by
alkaline phosphatase activity (3) and the latency of
sialic acid to hydrolysis by neuraminidase (2),
respectively. Contamination by microsomal membranes was assessed by the
activity of NADPH cytochrome c reductase (37).
Protein concentrations were determined by the method of Lowry as
modified by Markwell et al. (36).
Immunofluorescence and Western blot analysis. The monoclonal antibodies against MRP1 [MRP(m5) and MRP(m6)] and against MRP2 (M2III-6) were from Alexis Biochemicals. The polyclonal antibodies to MRP3, raised in rabbits against a 20-amino acid internal peptide sequence (ALL) and the 24-amino acid carboxyl terminus (FDS), were developed and described by Konig et al. (28). Markers for endothelial cells, rabbit anti-human von Willebrand factor (VWF), and mouse anti-human platelet endothelial cell adhesion molecule (PECAM-1) (clone WM-59) were purchased from Sigma Chemie. C219, a murine monoclonal antibody against MDR1 and MDR3, was from Signet Laboratories (Dedham, MA).
Placentas were dissected free of fetal membranes and frozen in isopentane precooled in liquid nitrogen, and then sections (10 µm) were cut on a cryomicrotome at
20°C. For studies with antibodies
MRP1(m6), MRP1(m5), MRP3(ALL), and PECAM-1, sections were fixed in 2%
paraformaldehyde in PBS. Acetone fixation (
20°C) was used for
studies with MRP3(FDS) and MRP2. Sections were blocked in BSA (Jackson
Immunoresearch Laboratories, West Grove, PA) and whole human serum
(Dako, Denmark) and then were incubated with antibodies for 2 h at
dilutions of 1:10 for MRP1(m5), MRP1(m6), and MRP2, 1:500 for VWF,
1:200 for MRP3(FDS), 1:500 for MRP3(ALL), and 1:100 for PECAM-1. After
four washes in PBS, sections were incubated for 45 min with the
secondary antibodies, indocarbocyanine (Cy3)-conjugated goat
anti-rabbit or anti-mouse IgG (Jackson Immunoresearch), or FITC-labeled
sheep anti-mouse or anti-rabbit IgG (ICN Biomedicals). Sections were
examined by confocal microscopy (Leica Instruments).
For Western blot analysis, basolateral and apical placental membranes
(100 µg) were diluted with sample buffer and heated to 56°C for 10 min before separation on a 7.5% SDS acrylamide gel. After transfer to
a nitrocellulose membrane and blocking in 5% milk and 0.4% BSA,
immunoblotting was performed with a 1-h incubation with antibodies
against MRP1, MRP2, and MRP3(FDS) diluted in Tris-buffered saline
containing 0.1% Tween 20. Signals were detected by means of enhanced
chemiluminescence (ECL-Plus; Amersham Pharmacia Biotech) using 1:20,000
dilutions of the secondary antibody, horseradish peroxidase-conjugated
goat anti-rabbit IgG, or sheep anti-mouse IgG (Bio-Rad, Munich, Germany).
Transport studies in placenta vesicles. The transport studies were performed at 37°C, as described previously (47), in transport medium containing 10 mM HEPES-Tris (pH = 7.4), 250 mM sucrose, 100 mM KNO3, 10 mM MgCl2, 0.2 mM CaCl2, 3 mM ATP, and an ATP-regenerating system (3 mM creatine phosphate and 100 µg/ml creatine phosphokinase). Transport medium (80 µl) was mixed with 20 µl vesicles (100 µg protein), and the reaction mixture was stopped by addition of 4 ml ice-cold stop solution (250 mM KCl, 25 mM MgSO4, and 10 mM HEPES-Tris, pH = 7.4) and then filtered under vacuum through 0.65-µm cellulose-nitrate filters. For the glycocholate studies, 100 µM cholic acid was added to the stop solution. Filters were washed with 2 × 4 ml stop solution, and radioactivity retained on the filter was measured in a liquid scintillation counter.
| |
RESULTS |
|---|
|
|
|---|
Amplification of MRP cDNA fragments by PCR. To screen for the presence of MRP-related proteins in term placenta, we performed PCR with specific primers for MRP1, MRP2, and MRP3 and then subcloned and sequenced the resulting PCR fragments. For MRP1, nested PCR was performed to increase the yield of product available for subcloning. All amplified PCR fragments were of the predicted length. The fragments of all three MRPs were 98-99% identical to the known nucleotide sequences.
Characterization of MRP-related cDNA clones in the placenta. To determine whether the three multidrug resistance-associated proteins expressed in the placenta were identical to, or variants of, those identified in other human tissues, a cDNA library panel was screened by PCR. With primers specific for MRP1, the screen gave 14 positive signals of the predicted size (580 bp). The rescreen of one positive subwell resulted in two positive colonies containing inserts of ~4.9 kb. Sequence analysis from the 5'-end showed 100% homology with MRP1 from base number 834 to the poly(A) tail. Similarly, the initial screen of the cDNA panel for MRP2 yielded six signals of ~1,770 bp. The rescreen yielded two colonies with inserts of ~4.9 kb. Sequencing from the 5'-end showed that the partial cDNA was 100% homologous with the published sequence of MRP2 beginning at exon 3 (base number 177). The initial screen of the cDNA panel with primers specific for MRP3 gave 10 positive signals of ~1,160 bp. Rescreening of one of the subplates gave rise to two positive colonies with inserts of ~3.4 kb. The partial cDNA clone was 100% identical to the published MRP3 sequence beginning at base 2000.
Immunolocalization of MRP in the placenta.
The MRP1(m6) antibody gave some weak fluorescent staining of the
syncytiotrophoblastic layer and the fetal blood vessels (Fig. 1A). The intensity of the
fluorescent signal was less in the syncytiotrophoblast and was not
observed in all terminal villi examined. An isotype-matched mouse
immunoglobulin showed background staining (Fig. 1B). Because others have reported that in a given tissue individual anti-MRP1 antibodies may show disparity in the target and intensity of staining (15), we also examined the fluorescent staining with the
MRP1(m5) antibody. Whereas trophoblastic staining was not evident with this antibody, the fetal blood vessels were strongly labeled, as
confirmed by double labeling with anti-human VWF, a cytoplasmic marker
for endothelial cells (Fig. 1C). The Cy3 [MRP1(m5)] and FITC (VWF) labels were clearly colocalized to the same vessel structure
(Fig. 1D). A reconstruction of the serial sections showed, however, that there was no overlap in the signals (Fig. 1E).
VWF is located within cytoplasmic vesicles, and this agrees with the punctate cytoplasmic staining observed; the MRP1 staining pattern was
continuous and suggested localization at the plasma membrane.
|
|
Characterization of basolateral and apical vesicle
preparations.
To confirm the results seen by immunofluorescence and to further
localize MRP1, MRP2, and MRP3 to the apical or basolateral membranes of
the syncytiotrophoblastic layer, membrane vesicles were prepared for
immunoblotting with anti-MRP antibodies. The vesicles were
characterized and found to be enriched for conventional markers (Table
1). The apical membranes were enriched
35-fold for alkaline phosphatase, whereas the enrichment of the
basolateral membranes was less (13.5-fold), as measured by the binding
of dihydroalprenolol (Table 1). The basolateral membranes were slightly more contaminated with the microsomal membrane marker NADPH cytochrome c reductase (6.9- vs. 1.7-fold for basolateral and apical,
respectively). The degree of cross contamination between basolateral
and apical membranes was similar: 2.9-fold for basolateral in the
apical preparation and 2.7-fold for apical in the basolateral
preparation. As an additional verification of the membrane
preparations, Western blotting was first performed with C219 against
P-glycoprotein (Fig. 3A). As
expected from previous reports (42), a signal was observed
only in the apical membranes. The Western blot of MRP1 demonstrated a
signal in the apical membranes with both MRP1(m5) (Fig. 3C)
and MRP1(m6) (Fig. 3D). The Western blot of MRP2 showed a
distinct signal in the apical membrane preparations (Fig.
3B). The anti-MRP3 FDS antibody was used for immunoblotting
of MRP3 (Fig. 4). An immunoreactive band
at ~170 kDa was detected in the apical preparation. A second more
intense band was prominent at ~60 kDa (Fig. 4A). Both
immunoreactive bands were displaced from the apical preparation when
the antibody was adsorbed with the antigenic FDS peptide (50 µM)
before immunoblotting (Fig. 4B). Interestingly, additional
bands appeared in the lane containing the basolateral membranes when
the antibody had been preadsorbed.
|
|
|
Glucuronide and glutathione conjugate transport in the trophoblasts
of the human placenta.
To correlate the expression of the MRP proteins in the apical membrane
of the syncytiotrophoblast layer with function, we tested for the
presence of ATP-dependent uptake of an anionic model substrate of MRP1
and MRP2 in apical vesicles. As a positive control for the integrity of
the isolated membrane preparation, we first measured the ATP-dependent
uptake of the bile salt glycocholate, the transport of which has been
well characterized (5, 47; Fig. 5A). Vesicles were also
incubated with the [14C]glutathione conjugate DNP-SG in
the absence and presence of ATP. As shown in this typical experiment
and repeated in three independent preparations, accumulation was
clearly ATP dependent (Fig. 5B).
Estradiol-17-
-glucuronide, a natural steroid conjugate whose
affinity for MRP isoforms has been well characterized, also exhibited
ATP-dependent accumulation in apical syncytiotrophoblast vesicles. When
tested at a concentration of 0.5 µM, uptake was 3.1 ± 0.3 pmol · mg
1 · 10 min
1 in the
presence of ATP and 2.0 ± 0.1 pmol · mg
1 · 10 min
1 in the
absence of ATP.
|
| |
DISCUSSION |
|---|
|
|
|---|
The MRP family of proteins mediates the ATP-dependent cellular efflux of a wide range of organic anionic compounds. Substrates for MRP1 and MRP2 include bilirubin glucuronosides and other glucuronide, glutathione, and sulfate conjugates (22, 23, 26). The rat Mrp3 has shown preferential ATP-dependent transport of glucuronide rather than glutathione conjugates (17) and of both monoanionic and dianionic bile salts (18). Human MRP3 transports DNP-SG, but its full spectrum of substrates has not been determined (29).
Our findings show that the human placenta at term expresses at least three members of the MRP protein family: MRP1, MRP2, and MRP3. We have isolated partial clones and determined that they are identical to those originally cloned from human lung (8) and liver (28, 43). The main immunoreactivity to MRP1 in term placenta was in the fetal blood vessels of the terminal and intermediate villi. As demonstrated by double labeling with an antibody to VWF, MRP1 was localized to the endothelium of the vessels. The separation of the Cy3 and FITC signals at higher magnification provides evidence that MRP1 is located within endothelial plasma membrane. Other investigators have recently reported the presence of MRP1 in endothelia, including primary cultures of bovine brain microvessels (19), a mouse brain capillary endothelial cell line (30), and in human brain endothelial cells in culture (46). The immunofluorescence study with the MRP(m6) antibody, but not MRP(m5), localized MRP1 to the syncytiotrophoblast, which is in agreement with results of Flens et al. (15) rather than with those of Sugawara et al. (48). Immunoblotting of plasma membrane preparations of the syncytiotrophoblast suggests an apical subcellular localization for this efflux pump.
MRP2 was detected by both immunofluorescence and Western blotting only in the apical membranes of the syncytiotrophoblast and not in fetal blood vessels. Its expression profile therefore differs from that of MRP1 and resembles that of P-glycoprotein, which is also absent from endothelium and present in apical membranes. The MRP3 protein was detected in the syncytiotrophoblast with the FDS antibody. Immunoblotting suggests an apical localization facing the maternal blood. The identity of the second immunoreactive band at ~60 kDa is not known, but its displacement by the immunogenic FDS peptide suggests that a degradative process has occurred during membrane or sample preparation. Many of the small fetal blood vessels were also stained by the FDS antibody, but these were not displaced by the antigenic peptide (Fig. 2). A second anti-MRP3 antibody (ALL) raised against a more proximal region of the protein also stained fetal blood vessel structures. MRP3 colocalized with PECAM-1, an endothelial cell membrane marker whose presence within endothelial cell junctions and at the luminal surface of endothelium in term placenta has been characterized (32). The lack of syncytiotrophoblast staining with the ALL anti-MRP3 antibody on paraformaldehyde-treated sections may reflect loss of antigenicity during tissue fixation.
Because the MRP transporters are important efflux pumps for anionic
conjugates in mammalian cells, we hypothesized that apical membrane
vesicles from the syncytiotrophoblast would exhibit ATP-dependent transport of model substrates. Our transport studies indeed show that
ATP stimulated the uptake of [14C]DNP-SG, a substrate
with high affinity for MRP isoforms (26, 27).
ATP-dependent uptake of [3H]estradiol-17-
-glucuronide
was also observed. However, this substrate is transported by MRP
isoforms with high affinity [Michaelis constant
(Km) = 1-7 µM; see Ref. 26] and by
MDR1 with much lower affinity (Km = 65 µM; see Ref. 20). Therefore, the rate of transport that we report is
a composite of both high- and low-affinity processes and is influenced
by relative abundance of the MRP vs. MDR1 proteins.
The physiological function of MRP-related proteins in the
syncytiotrophoblast layer remains speculative. It is logical to expect
that the apical trophoblastic expression of an ATP-dependent pump
capable of transporting organic anions such as sulfate, glucuronide, and glutathione conjugates out of the cell would be well placed to
exert a protective role in the human placenta. In particular, MRP2 was
shown to enhance resistance of transfected cells to etoposide, cisplatin, doxorubicin, and vincristine (12). In addition,
the placenta possesses significant glutathione S-transferase
activity, and the
-isozyme of glutathione S-transferase
protein is detectable upon immunoblotting (1, 38). The
placenta, therefore, retains the capacity to bioinactivate
pharmacologically active molecules and secrete them in the maternal
circulation. Likewise, many bile salts produced by the fetal liver are
sulfated and amidated (41). Such dianionic sulfated bile
salts are substrates for MRP1 and MRP2 (22, 23), and their
elimination via maternal blood may be facilitated. In addition to its
steroidogenic activity, the placenta also biosynthesizes the
polypeptide hormones endothelin-1 and -3, which are presumed to exert
both autocrine and paracrine effects in placental tissue (16,
45). Endothelin receptors are present on fetal vessels, on both
membranes of the syncytiotrophoblast, and on extravillous
cytotrophoblasts (16, 39). Secretion of endothelin-1 from
trophoblastic cells in culture has been demonstrated (6).
The recent finding that rat Mrp2 is a candidate for the ATP-dependent
transport of endothelin-1 (33) raises the possibility of a
role for MRP2 in the release and regulation of endothelin-1 levels in placenta.
Perspectives
An exacting study of the presence and function of all MRP-related proteins in human placental throughout gestation is required since at least three additional MRP family transporters have been identified (4, 26). Moreover, a definitive role for MRPs in placental physiology cannot yet be assigned. In particular, the role of MRPs in the fetal capillary placental barrier is not obvious. The endothelial cells of the fetal vessels are continuous, linked by tight and adherent junctions, secrete a basement membrane, and are thought to contribute substantially to total transplacental resistance to solute transfer (32). The paracellular passage of substances such as horseradish peroxidase has been detected, but the accessibility of charged amphiphilic anions across the fetal endothelial cells in either the fetal or maternal directions has not been studied. Although the subcellular location of MRP1 and MRP3 within the endothelial cells could not be ascertained from these studies, it is tempting to speculate that MRPs may exert a protective role by retrieving toxic substances from the fetal blood that have gained access through the paracellular route. Taken together, our findings that MRP isoforms are localized to fetal blood vessels and/or the syncytiotrophoblast of the chorionic villi suggest a role in the vectorial transport capabilities of the placenta. This in turn would serve as a barrier to protect the fetus from noxious substances and would allow the active secretion of endogenous, anionic compounds in the fetal-maternal direction.| |
ACKNOWLEDGEMENTS |
|---|
We thank the Department of Dental Surgery, University of Zürich, for use of their technical facilities and gratefully acknowledge Dr. D. Keppler, Deutsches Krebsforschungszentrum Heidelberg, Germany, for generous gifts of the MRP3 antibodies and for critical review of the manuscript.
| |
FOOTNOTES |
|---|
This work was supported by Hartmann Müller-Stiftung für medizinische Forschung Grant no. 726 (to M. V. St-Pierre), by Marie Heim Voegtlin fellowship no. 3234-055037.98 (to M. V. St-Pierre), and by Grants 31-056020.98 (to M. V. St-Pierre) and 31-45536.95 (to P. J. Meier) from the National Science Foundation, Switzerland.
Address for reprint requests and other correspondence: M. V. St. Pierre, Div. of Clinical Pharmacology, Dept. of Internal Medicine, Univ. Hospital, CH-8091 Zürich, Switzerland (E-mail: stpierre{at}kpt.unizh.ch).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 10 January 2000; accepted in final form 21 May 2000.
| |
REFERENCES |
|---|
|
|
|---|
1.
Ahmad, H,
Wilson DE,
Fritz RR,
Singh SV,
Medh RD,
Nagle GT,
Awasthi YC,
and
Kurosky A.
Primary and secondary structural analyses of glutathione S-transferase pi from human placenta.
Arch Biochem Biophys
278:
398-408,
1990[Web of Science][Medline].
2.
Aminoff, D.
Methods for the quantitative estimation of N-acetylneuraminic acid and their application to hydrolysates of sialomucoids.
Biochem J
81:
384-392,
1961[Web of Science][Medline].
3.
Booth, AG,
Olaniyan RO,
and
Vanderpuye OA.
An improved method for the preparation of human placental syncytiotrophoblast microvilli.
Placenta
1:
327-336,
1980[Web of Science][Medline].
4.
Borst, P,
Evers R,
Kool M,
and
Wijnholds J.
The multidrug resistance protein family.
Biochim Biophys Acta
1461:
347-357,
1999[Medline].
5.
Bravo, P,
Marin JJ,
Beveridge MJ,
and
Novak DA.
Reconstitution and characterization of ATP-dependent bile acid transport in human and rat placenta.
Biochem J
311:
479-485,
1995.
6.
Cervar, M,
Kainer F,
Jones CJP,
and
Desoye G.
Altered release of endothelin-1,2 and thromboxane B2 from trophoblastic cells in pre-eclampsia.
Eur J Clin Invest
26:
30-37,
1996[Web of Science][Medline].
7.
Chomczynski, P,
and
Sacchi N.
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.
Anal Biochem
162:
156-159,
1987[Web of Science][Medline].
8.
Cole, SP,
Bhardwaj G,
Gerlach JH,
Mackie JE,
Grant CE,
Almquist KC,
Stewart AJ,
Kurz EU,
Duncan AM,
and
Deeley RG.
Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line.
Science
258:
1650-1654,
1992
9.
Colombo, C,
Zuliani G,
Ronchi M,
Breidenstein J,
and
Setchell KD.
Biliary bile acid composition of the human fetus in early gestation.
Pediatr Res
21:
197-200,
1987[Web of Science][Medline].
10.
Cordon-Cardo, C,
O'Brien JP,
Boccia J,
Casals D,
Bertino JR,
and
Melamed MR.
Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues.
J Histochem Cytochem
38:
1277-1287,
1990[Abstract].
11.
Coukos, G,
Makrigiannakis A,
Amin K,
Albelda S,
and
Coutifaris C.
Platelet-endothelial cell adhesion molecule-1 is expressed by a subpopulation of human trophoblasts: a possible mechanism for trophoblast-endothelial interaction during haemochorial placentation.
Mol Hum Reprod
4:
357-367,
1998
12.
Cui, Y,
König J,
Buchholz U,
Spring H,
Leier I,
and
Keppler D.
Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells.
Mol Pharmacol
55:
929-937,
1999
13.
El-Mir, MYA,
Eleno N,
Serrano MA,
Bravo P,
and
Marin JG.
Bicarbonate-induced activation of taurocholate transport across the basal plasma membrane of human term trophoblast.
Am J Physiol Gastrointest Liver Physiol
260:
G887-G894,
1991
14.
Faller, DP,
Egan DA,
and
Ryan MP.
Evidence for location of the CFTR in human placental apical membrane vesicles.
Am J Physiol Cell Physiol
269:
C148-C155,
1995
15.
Flens, MJ,
Zaman GJR,
van der Valk P,
Izquierdo MA,
Schroeijers AB,
Scheffer GL,
van der Groep P,
de Haas M,
Meijer CJL,
and
Scheper RJ.
Tissue distribution of the multidrug resistance protein.
Am J Pathol
148:
1237-1247,
1996[Abstract].
16.
Handwerger, S.
Endothelins and the placenta.
J Lab Clin Med
125:
679-681,
1995[Web of Science][Medline].
17.
Hirohashi, T,
Suzuki H,
and
Sugiyama Y.
Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3).
J Biol Chem
274:
15181-15185,
1999
18.
Hirohashi, T,
Suzuki H,
Takikawa H,
and
Sugiyama Y.
ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3).
J Biol Chem
275:
2905-1290,
2000
19.
Huai-Yun, H,
Secrest DT,
Mark KS,
Carney D,
Brandquist C,
Elmquist WF,
and
Miller DW.
Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells.
Biochem Biophys Res Commun
243:
816-820,
1998[Web of Science][Medline].
20.
Huang, L,
Hoffman T,
and
Vore M.
Adenosine triphosphate-dependent transport of estradiol-17beta(beta-D-glucuronide) in membrane vesicles by MDR1 expressed in insect cells.
Hepatology
28:
1371-1377,
1998[Web of Science][Medline].
21.
Ishikawa, T.
ATP/Mg2+-dependent cardiac transport system for glutathione S-conjugates. A study using rat heart sarcolemma vesicles.
J Biol Chem
264:
17343-17348,
1989
22.
Jedlitschky, G,
Leier I,
Buchholz U,
Barnouin K,
Kurz G,
and
Keppler D.
Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump.
Cancer Res
56:
988-994,
1996
23.
Jedlitschky, G,
Leier I,
Buchholz U,
Hummel-Eisenbeiss J,
Burchell B,
and
Keppler D.
ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2.
Biochem J
327:
305-310,
1997.
24.
Kaufmann, P,
and
Scheffen I.
Placental development.
In: Fetal and Neonatal Physiology, edited by Polin RA,
and Fox WW.. Philadelphia, PA: Saunders, 1992, p. 47-56.
25.
Kelley, LK,
Smith CH,
and
King BF.
Isolation and partial characterization of the basal cell membrane of human placental trophoblast.
Biochim Biophys Acta
734:
91-98,
1983[Medline].
26.
Keppler, D,
Cui Y,
Konig J,
Nies I,
and
Nies A.
Export pumps for anionic conjugates encoded by MRP genes.
Adv Enzyme Regul
39:
237-246,
1999[Web of Science][Medline].
27.
Konig, J,
Nies AT,
Cui Y,
Leier I,
and
Keppler D.
Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance.
Biochim Biophys Acta
1461:
377-394,
1999[Medline].
28.
Konig, J,
Rost D,
Cui Y,
and
Keppler D.
Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane.
Hepatology
29:
1156-1163,
1999[Web of Science][Medline].
29.
Kool, M,
van der Linden M,
de Haas M,
Scheffer GL,
de Vree JM,
Smith AJ,
Jansen G,
Peters GJ,
Ponne N,
Scheper RJ,
Elferink RP,
Baas F,
and
Borst P.
MRP3, an organic anion transporter able to transport anti-cancer drugs.
Proc Natl Acad Sci USA
96:
6914-6919,
1999
30.
Kusuhara, H,
Suzuki H,
Naito M,
Tsuro T,
and
Sugiyama Y.
Characterization of efflux transport of organic anions in a mouse brain capillary endothelial cell line.
J Pharmacol Exp Ther
285:
1260-1265,
1998
31.
Lankas, GR,
Wise D,
Cartwright ME,
Pippert T,
and
Umbenhauer DR.
Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice.
Reprod Toxicol
12:
457-463,
1998[Web of Science][Medline].
32.
Leach, L,
Clark P,
Lampugnani M-G,
Arroyo AG,
Dejana E,
and
Firth JA.
Immunoelectron characterisation of the inter-endothelial junctions of human term placenta.
J Cell Sci
104:
1073-1081,
1993[Abstract].
33.
Madon, J,
Hagenbuch B,
Landmann L,
Meier PJ,
and
Stieger B.
Transport function and hepatocellular localization of mrp6 in rat liver.
Mol Pharmacol
57:
634-641,
2000
34.
Mansier, P,
Charlemagne D,
Rossi B,
Preteseille M,
Swynghedauw B,
and
Lelievre L.
Isolation of impermeable inside-out vesicles from an enriched sarcolemma fraction of rat heart.
J Biol Chem
258:
6628-6635,
1983
35.
Marin, JJ,
Serrano MA,
el-Mir MY,
Eleno N,
and
Boyd CA.
Bile acid transport by basal membrane vesicles of human term placental trophoblast.
Gastroenterology
99:
1431-1438,
1990[Web of Science][Medline].
36.
Markwell, MAK,
Haas SM,
Bieber LL,
and
Tolbert NE.
A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples.
Anal Biochem
87:
206-210,
1978[Web of Science][Medline].
37.
Masters, BS,
Williams CH,
and
Kamin H.
The preparation and properties of microsomal TPNH-cytochrome c reductase from pig liver.
Methods Enzymol
10:
565-573,
1967.
38.
Mcrobie, DJ,
Glover DD,
and
Tracy TS.
Effects of gestational and overt diabetes on human placental cytochromes P450 and glutathione S-transferase.
Drug Metab Dispos
26:
367-371,
1998
39.
Mondon, F,
Anouar A,
and
Ferré F.
Endothelin receptor subtypes in the microvillous trophoblastic membrane of early gestation and term human placentas.
Eur J Endocrinol
139:
231-237,
1998[Abstract].
40.
Mylona, P,
Hoyland JA,
and
Sibley CP.
Sites of mRNA expression of the cystic fibrosis (CF) and multidrug resistance (MDR1) genes in the human placenta of early pregnancy: no evidence for complementary expression.
Placenta
20:
493-496,
1999[Web of Science][Medline].
41.
Nakagawa, M,
and
Setchell KD.
Bile acid metabolism in early life: studies of amniotic fluid.
J Lipid Res
31:
1089-1098,
1990[Abstract].
42.
Nakamura, Y,
Ikeda S-I,
Furukawa T,
Sumizawa T,
Tani A,
Akiyama S-I,
and
Nagata Y.
Function of P-glycoprotein expressed in placenta and mole.
Biochem Biophys Res Commun
235:
849-853,
1997[Web of Science][Medline].
43.
Paulusma, CC,
Kool M,
Bosma PJ,
Scheffer GL,
ter Borg F,
Scheper RJ,
Tytgat GN,
Borst P,
Baas F,
and
Oude Elferink RP.
A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome.
Hepatology
25:
1539-1542,
1997[Web of Science][Medline].
44.
Redman, C,
Sargent I,
and
Starkey P.
The Human Placenta. Oxford, UK: Blackwell Scientific, 1993.
45.
Robert, B,
Malassiné A,
Bourgeois C,
Mignot T-M,
Cronier L,
Ferré F,
and
Duc-Goiran P.
Expression of endothelin precursor genes in human trophoblast in culture.
Eur J Endocrinol
134:
490-496,
1996
46.
Seetharaman, S,
Barrand MA,
Maskell L,
and
Scheper RJ.
Multidrug resistance-related transport proteins in isolated human brain microvessels and in cells cultured from these isolates.
J Neurochem
70:
1151-1159,
1998[Web of Science][Medline].
47.
Serrano, MA,
Brites D,
Larena MG,
Monte MJ,
Bravo MP,
Oliveira N,
and
Marin JJ.
Beneficial effect of ursodeoxycholic acid on alterations induced by cholestasis of pregnancy in bile acid transport across the human placenta.
J Hepatol
28:
829-839,
1998[Web of Science][Medline].
48.
Sugawara, I,
Akiyama S,
Scheper RJ,
and
Itoyama S.
Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP.
Cancer Lett
112:
23-31,
1997[Web of Science][Medline].
49.
Williams, LT,
Jarett L,
and
Lefkowitz RJ.
Adipocyte
-adrenergic receptors.
J Biol Chem
251:
3096-3104,
1976
This article has been cited by other articles:
![]() |
S. Minami, K. Ito, M. Honma, Y. Ikebuchi, N. Anzai, Y. Kanai, T. Nishida, S. Tsukita, S. Sekine, T. Horie, et al. Posttranslational regulation of Abcc2 expression by SUMOylation system Am J Physiol Gastrointest Liver Physiol, February 1, 2009; 296(2): G406 - G413. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Petrovic, J.-H. Wang, and M. Piquette-Miller Effect of Endotoxin on the Expression of Placental Drug Transporters and Glyburide Disposition in Pregnant Rats Drug Metab. Dispos., September 1, 2008; 36(9): 1944 - 1950. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Aleksunes, Y. Cui, and C. D. Klaassen Prominent Expression of Xenobiotic Efflux Transporters in Mouse Extraembryonic Fetal Membranes Compared with Placenta Drug Metab. Dispos., September 1, 2008; 36(9): 1960 - 1970. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Garland, K. M. Abildskov, T.-w. Kiu, S. S. Daniel, P. Weldy, and R. I. Stark Placental Transfer and Fetal Elimination of Morphine-3-{beta}-glucuronide in the Pregnant Baboon Drug Metab. Dispos., September 1, 2008; 36(9): 1859 - 1868. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. May, V. Minarikova, K. Linnemann, M. Zygmunt, H. K. Kroemer, C. Fusch, and W. Siegmund Role of the Multidrug Transporter Proteins ABCB1 and ABCC2 in the Diaplacental Transport of Talinolol in the Term Human Placenta Drug Metab. Dispos., April 1, 2008; 36(4): 740 - 744. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Zhou, S. B. Naraharisetti, H. Wang, J. D. Unadkat, M. F. Hebert, and Q. Mao The Breast Cancer Resistance Protein (Bcrp1/Abcg2) Limits Fetal Distribution of Glyburide in the Pregnant Mouse: An Obstetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study Mol. Pharmacol., March 1, 2008; 73(3): 949 - 959. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Rahi, T Heikkinen, J Hakkola, K Hakala, O Wallerman, M Wadelius, C Wadelius, and K Laine Influence of adenosine triphosphate and ABCB1 (MDR1) genotype on the P-glycoprotein-dependent transfer of saquinavir in the dually perfused human placenta Human and Experimental Toxicology, January 1, 2008; 27(1): 65 - 71. [Abstract] [PDF] |
||||
![]() |
M. Rahi, T. Heikkinen, S. Hartter, J. Hakkola, K. Hakala, O. Wallerman, M. Wadelius, C. Wadelius, and K. Laine Placental transfer of quetiapine in relation to P-glycoprotein activity J Psychopharmacol, September 1, 2007; 21(7): 751 - 756. [Abstract] [PDF] |
||||
![]() |
T. Mose, L. E. Knudsen, M. Hedegaard, and G. K. Mortensen Transplacental Transfer of Monomethyl Phthalate and Mono(2-ethylhexyl) Phthalate in a Human Placenta Perfusion System International Journal of Toxicology, May 1, 2007; 26(3): 221 - 229. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. F. McDonagh Movement of Bilirubin and Bilirubin Conjugates Across the Placenta Pediatrics, May 1, 2007; 119(5): 1032 - 1033. [Full Text] [PDF] |
||||
![]() |
V. Petrovic, S. Teng, and M. Piquette-Miller REGULATION OF DRUG TRANSPORTERS: DURING INFECTION AND INFLAMMATION Mol. Interv., April 1, 2007; 7(2): 99 - 111. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Wang, X. Wu, K. Hudkins, A. Mikheev, H. Zhang, A. Gupta, J. D. Unadkat, and Q. Mao Expression of the breast cancer resistance protein (Bcrp1/Abcg2) in tissues from pregnant mice: effects of pregnancy and correlations with nuclear receptors. Am J Physiol Endocrinol Metab, December 1, 2006; 291(6): E1295 - E1304. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Deeley, C. Westlake, and S. P. C. Cole Transmembrane Transport of Endo- and Xenobiotics by Mammalian ATP-Binding Cassette Multidrug Resistance Proteins. Physiol Rev, July 1, 2006; 86(3): 849 - 899. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Evseenko, J. W. Paxton, and J. A. Keelan ABC drug transporter expression and functional activity in trophoblast-like cell lines and differentiating primary trophoblast Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2006; 290(5): R1357 - R1365. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Briz, R. I. R. Macias, M. J. Perez, M. A. Serrano, and J. J. G. Marin Excretion of fetal biliverdin by the rat placenta-maternal liver tandem Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2006; 290(3): R749 - R756. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Grube, H. M. z. Schwabedissen, K. Draber, D. Prager, K.-U. Moritz, K. Linnemann, C. Fusch, G. Jedlitschky, and H. K. Kroemer EXPRESSION, LOCALIZATION, AND FUNCTION OF THE CARNITINE TRANSPORTER OCTN2 (SLC22A5) IN HUMAN PLACENTA Drug Metab. Dispos., January 1, 2005; 33(1): 31 - 37. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. V. St-Pierre, T. Stallmach, A. Freimoser Grundschober, J.-F. Dufour, M. A. Serrano, J. J. G. Marin, Y. Sugiyama, and P. J. Meier Temporal expression profiles of organic anion transport proteins in placenta and fetal liver of the rat Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2004; 287(6): R1505 - R1516. [Abstract] [Full Text] [PDF] |
||||
![]() |
C G Dietrich, A Geier, and R P J Oude Elferink ABC of oral bioavailability: transporters as gatekeepers in the gut Gut, December 1, 2003; 52(12): 1788 - 1795. [Full Text] [PDF] |
||||
![]() |
D. E. Atkinson, S. L. Greenwood, C. P. Sibley, J. D. Glazier, and L. J. Fairbairn Role of MDR1 and MRP1 in trophoblast cells, elucidated using retroviral gene transfer Am J Physiol Cell Physiol, September 1, 2003; 285(3): C584 - C591. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Trauner and J. L. Boyer Bile Salt Transporters: Molecular Characterization, Function, and Regulation Physiol Rev, April 1, 2003; 83(2): 633 - 671. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Leazer and C. D. Klaassen The Presence of Xenobiotic Transporters in Rat Placenta Drug Metab. Dispos., February 1, 2003; 31(2): 153 - 167. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Granger Maternal and fetal adaptations during pregnancy: lessons in regulatory and integrative physiology Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2002; 283(6): R1289 - R1292. [Full Text] [PDF] |
||||
![]() |
J. B. Pritchard Comparative models and biological stress Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2002; 283(4): R807 - R809. [Full Text] [PDF] |
||||
![]() |
M. Inuyama, F. Ushigome, A. Emoto, N. Koyabu, S. Satoh, K. Tsukimori, H. Nakano, H. Ohtani, and Y. Sawada Characteristics of L-lactic acid transport in basal membrane vesicles of human placental syncytiotrophoblast Am J Physiol Cell Physiol, September 1, 2002; 283(3): C822 - C830. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Gerk and M. Vore Regulation of Expression of the Multidrug Resistance-Associated Protein 2 (MRP2) and Its Role in Drug Disposition J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 407 - 415. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. Audus, M. J. Soares, and J. S. Hunt Characteristics of the Fetal/Maternal Interface with Potential Usefulness in the Development of Future Immunological and Pharmacological Strategies J. Pharmacol. Exp. Ther., May 1, 2002; 301(2): 402 - 409. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Tanabe, I. Ieiri, N. Nagata, K. Inoue, S. Ito, Y. Kanamori, M. Takahashi, Y. Kurata, J. Kigawa, S. Higuchi, et al. Expression of P-glycoprotein in Human Placenta: Relation to Genetic Polymorphism of the Multidrug Resistance (MDR)-1 Gene J. Pharmacol. Exp. Ther., June 1, 2001; 297(3): 1137 - 1143. [Abstract] [Full Text] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |